Moreover, the phase II PePS2 study of pembrolizumab monotherapy in 60 patients with NSCLC with ECOG PS 2 included 24 (40%) given as first-line therapy and 25% (15 patients) with PD-L1 TPS ≥ 50% [25]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.